"Klinische Studien sind der Schlüssel zu neuen Erkenntnissen in der Diagnostik und Therapie von Erkrankungen. Wir sind stolz, in der Schweiz dazu beizutragen."

Klaudia Georgi, Director Clinical Research MSD Switzerland & Austria

15

In der Schweiz zugelassene First-in-Class-Medikamente seit 2000

(Stand: 10/2018)

25

Durchschnittliche Anzahl klinische Studien in der Schweiz pro Jahr

(Stand: 10/2018)

70

Millionen Schweizer Franken in die Forschung investiert, seit 2012

(Stand: 10/2018)

Die klinische Forschung von MSD Schweiz wird in unserer Niederlassung im Citybay in Luzern koordiniert.
Unsere Niederlassungen

Das klinische Studienprogramm von MSD in der Schweiz ist breit gefächert (Stand: 10/2018)

Laufende klinische Studien von MSD in der Schweiz (Stand: 10/2018)

Infektiologie

Studie

Durchführungsort

Hepatitis C

MK-5172-017: A Long-Term Follow-Up Study to Evaluate the Durability of Virologic Response and/or Viral Resistance Patterns of Subjects with Chronic Hepatitis C Who Have Been Previously Treated With MK-5172 in a Prior Clinical Trial

Zürich

HIV

MK-1439A-021: A Phase III Multicenter, Double-Blind, Randomized, Active Comparator-Controlled Clinical Trial to Evaluate the Safety and Efficacy of MK-1439A Once-Daily Versus ATRIPLA™ Once-Daily in Treatment-Naïve HIV-1 Infected

Genf, Lausanne, Zürich

MK-1439A-024: A Phase III Multicenter, Open-Label, Randomized Study to Evaluate a Switch to MK-1439A in HIV-1-Infected Subjects Virologically Suppressed on a Regimen of a Ritonavir-boosted Protease Inhibitor and Two Nucleoside Reverse Transcriptase Inhibitors (NRTIs)

Bern, Genf, Lausanne, Zürich

Pilzerkrankungen

MK-5592-069: Phase 3 Randomized Study of the Efficacy and Safety of Posaconazole Versus Voriconazole for the Treatment of Invasive Aspergillosis in Adults and Adolescents (Phase 3; Protocol No. MK-5592-069)

Basel, Bern, Zürich

Kardiologie

Studie

Durchführungsort

Herzinsuffizienz

MK-1242-001 (VICTORIA): A Randomized Parallel-Group, Placebo-Controlled, Double-Blind, Event-Driven, Multi-Center Pivotal Phase III Clinical Outcome Trial of Efficacy and Safety of the Oral sGC Stimulator Vericiguat in Subjects with Heart Failure with Reduced Ejection Fraction (HFrEF) - VerICiguaT Global Study in Subjects With Heart Failure With Reduced Ejection Fraction (VICTORIA)

Basel, Lausanne, Lugano

Onkologie

Studie

Durchführungsort

Brustkrebs

MK-3475-119/KEYNOTE-119: A Randomized Open-Label Phase III Study of Single Agent Pembrolizumab Versus Single Agent Chemotherapy Per Physician's Choice for Metastatic Triple Negative Breast Cancer (mTNBC)

Bellinzona, Bern, Zürich

B-Zell-Lymphom

MK-3475-170/KEYNOTE 170: A Phase II Study of Pembrolizumab (MK-3475) in Subjects with Relapsed or Refractory Primary Mediastinal Large B-cell Lymphoma (rrPMBCL) or Relapsed or Refractory Richter Syndrome (rrRS)

Bellinzona

Fortgeschrittene solide Tumore

MK-3475-587/KEYNOTE-587: Long-term Safety and Efficacy Extension Study for Participants with Advanced Tumors Who Are Currently on Treatment or in Follow-up in a Pembrolizumab (MK-3475) Study

Zürich

Kolorektales Karzinom

MK-3475-177/KEYNOTE-177: A Phase III Study of Pembrolizumab (MK-3475) vs. Chemotherapy in Microsatellite Instability-High (MSI-H) or Mismatch Repair Deficient (dMMR) Stage IV Colorectal Carcinoma

Basel, Genf, St. Gallen, Zürich

Kopf-und Halskrebs

MK-3475-040/KEYNOTE-040: A Phase III Randomized Trial of MK-3475 (Pembrolizumab) versus Standard Treatment in Subjects with Recurrent or Metastatic Head and Neck Cancer

Bern, Genf, Luzern

MK-3475-048/KEYNOTE-048: A Phase 3 Clinical Trial of Pembrolizumab (MK-3475) in First Line Treatment of Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma

Basel, Zürich

Lungenkrebs

MK-3475/KEYNOTE-654-04/ECHO-305-04: A Phase 2, Randomized, Double-Blind Study of Pembrolizumab (MK-3475) Plus Epacadostat (INCB024360) Versus Pembrolizumab Plus Placebo as First-Line Treatment in Patients with Metastatic Non-Small Cell Lung Cancer Expressing High Levels of PD-L1

Bellinzona, Bern, Genf, Winterthur, Zürich

MK-3475-042/KEYNOTE-042: A Randomized, Open Label, Phase III Study of Overall Survival Comparing Pembrolizumab (MK-3475) Versus Platinum Based Chemotherapy in Treatment Naïve Subjects With PD-L1 Positive Advanced or Metastatic Non-Small Cell Lung Cancer

Basel, Bern, Freiburg

MK-3475-495/KEYNOTE-495; KeyImPaCT: A Phase 2 Precision Oncology Study of Biomarker-Directed, Pembrolizumab-(MK-3475, SCH 900475) Based Combination Therapy for Advanced Non-Small Cell Lung Cancer

Basel, Chur, Genf, St. Gallen, Zürich

MK-3475-604/KEYNOTE-604: A Phase 3 Randomized, Double-Blind, Placebo-controlled Trial of Pembrolizumab (MK-3475/SCH900475) in Combination with Etoposide/Platinum (Cisplatin or Carboplatin) for the First-line Treatment of Subjects with Extensive Stage Small Cell Lung Cancer

Chur, Lausanne, Zürich

Magenkrebs

MK-3475-062/KEYNOTE-062: A Randomized, Active-Controlled, Partially Blinded, Biomarker Select, Phase III Clinical Trial of Pembrolizumab as Monotherapy and in Combination with Cisplatin+5-Fluorouracil Versus Placebo+Cisplatin+5-Fluorouracil as First-Line Treatment in Subjects with Advanced Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma

Basel, Bern, Chur, Lausanne, Zürich

Melanom

MK-3475-002/KEYNOTE-002: Randomized, Phase II Study of Pembrolizumab (MK-3475) Versus Chemotherapy in Patients with Advanced Melanoma

Basel, Lausanne, Zürich

MK-3475-252/KEYNOTE-252 / ECHO-301: A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study of Pembrolizumab (MK-3475) in Combination with Epacadostat or Placebo in Subjects with Unresectable or Metastatic Melanoma

Genf, Lausanne, Zürich

MK-3475-716/KEYNOTE-716: Adjuvant Therapy with Pembrolizumab Versus Placebo in Resected High-risk Stage II Melanoma: A Randomized, Double-blind Phase 3 Study

Bellinzona, Bern, Chur, Genf, Lausanne, Sion, St. Gallen, Zürich

Prostatakrebs

MK-3475-199/KEYNOTE-199: Phase II Trial of Pembrolizumab (MK-3475) in Subjects with Metastatic Castration-Resistant Prostate Cancer (mCRPC)

Basel, Chur, Luzern, St. Gallen

Zur Übersicht der schweizweiten Studien, die Teilnehmende suchen. www.kofam.ch

Wir möchten Menschen mit Krebs Hoffnung schenken

Wir investieren in die Entwicklung innovativer onkologischer Medikamente, um Menschen mit Krebserkrankungen zu helfen.

Mehr erfahren